| 埃博拉病毒疫苗研究进展 |
| |
| 引用本文： | 杨利敏,李晶,高福,刘文军.埃博拉病毒疫苗研究进展[J].生物工程学报,2015,31(1):1-23. |
| |
| 作者姓名： | 杨利敏 李晶 高福 刘文军 |
| |
| 作者单位： | 1. 中国科学院微生物研究所 病原微生物与免疫学重点实验室，北京 100101,1. 中国科学院微生物研究所 病原微生物与免疫学重点实验室，北京 100101,1. 中国科学院微生物研究所 病原微生物与免疫学重点实验室，北京 100101 2. 中国疾病预防控制中心，北京 102206,1. 中国科学院微生物研究所 病原微生物与免疫学重点实验室，北京 100101 |
| |
| 基金项目： | “艾滋病和病毒性肝炎等重大传染病防治”科技重大专项 (No. 2013ZX10004-610)，国家自然科学基金 (Nos. 31100644, 31402216, 81101253)，中国科学院重点部署项目 (No. KSZD-EW-Z-005-001) 资助。 |
| |
| 摘 要： | 埃博拉病毒是一种可引起人和非人灵长类动物出血热传染病的最为致命的烈性病毒,致死率可达90%。2014年在西非爆发的埃博拉疫情引起了全世界的关注。疫苗接种是预防和控制传染病最为常规和有效的方法,尽管目前还没有正式获得批准上市的埃博拉病毒疫苗,但是已有多个尚处于研究阶段的疫苗在非人灵长类动物上取得了很好的保护效果,并有几个已进入临床Ⅰ期试验阶段,有望尽快用于本次埃博拉疫情的防控。本文对目前处于研究阶段的多个类型的埃博拉病毒疫苗进行了综述,为相关研究人员提供参考。
|
| 关 键 词： | 埃博拉病毒 疫苗 腺病毒 水疱性口炎病毒 病毒样颗粒 |
| 收稿时间： | 2014/10/27 0:00:00 |
Overview of Ebola virus vaccine |
| |
| Limin Yang,Jing Li,George Fu Gao and Wenjun Liu.Overview of Ebola virus vaccine[J].Chinese Journal of Biotechnology,2015,31(1):1-23. |
| |
| Authors: | Limin Yang Jing Li George Fu Gao and Wenjun Liu |
| |
| Institution: | 1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China 2. Chinese Center for Disease Control and Prevention, Beijing 102206, China and 1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China |
| |
| Abstract: | Ebola virus (EBOV) causes hemorrhagic fever, resulting in mortality rates as high as 90% among infected humans and non-human primates (NHPs). The 2014 Ebola epidemic in West Africa is the severest in history, leading to WHO taking all control measures to stop any possibility of cross-border outbreaks.?Because no licensed vaccines or effective therapeutics against EBOV are available, the current outbreak management has been limited to palliative care and barrier methods to prevent transmission. Several promising experimental EBOV vaccines have demonstrated protection in NHPs against lethal EBOV challenge, and some progresses have been made through clinical trials of EBOV vaccine candidates. It is believed there will be some licensed vaccine available in the near future to control EBOV outbreaks. In this review we provide some insights for further development of EBOV vaccines. |
| |
| Keywords: | Ebola virus vaccine adenovirus vesicular stomatitis virus virus-like particles |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《生物工程学报》浏览原始摘要信息 |
| 点击此处可从《生物工程学报》下载免费的PDF全文 |
|
